An interesting new paper on the value of biosimilars from the folks at Amundsen Consulting. The paper is appropriately titled, “Who Saves?” The answer isn’t what patients want to hear.
Per the report:
“It may be difficult for patients, physicians, and advocates to understand the value of biosimilar therapies: Because patient costs are not likely to decline, use of biosimilars may be especially difficult to rationalize for those patients who are already gaining clinical benefits from innovator therapies. Without the realization and effective communication of how payers will use savings to support patient care or reduce cost, the value of biosimilars to the U.S. healthcare system will be limited ... Therefore, it is critical that the savings recognized by other parties translate into meaningful improvements in access or new programs/initiatives that advance patient care. Moreover, they need to be communicated to patients and plan sponsors effectively."
The complete paper can be found here.